WO2005020887A3 - Method for treatment of severe acute respiratory syndrome - Google Patents

Method for treatment of severe acute respiratory syndrome Download PDF

Info

Publication number
WO2005020887A3
WO2005020887A3 PCT/US2004/020447 US2004020447W WO2005020887A3 WO 2005020887 A3 WO2005020887 A3 WO 2005020887A3 US 2004020447 W US2004020447 W US 2004020447W WO 2005020887 A3 WO2005020887 A3 WO 2005020887A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
acute respiratory
respiratory syndrome
severe acute
compounds
Prior art date
Application number
PCT/US2004/020447
Other languages
French (fr)
Other versions
WO2005020887A2 (en
Inventor
John M Fidler
Karen S Leu
Original Assignee
Pharmagenesis Inc
John M Fidler
Karen S Leu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmagenesis Inc, John M Fidler, Karen S Leu filed Critical Pharmagenesis Inc
Publication of WO2005020887A2 publication Critical patent/WO2005020887A2/en
Publication of WO2005020887A3 publication Critical patent/WO2005020887A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

The use of triptolide compounds for treatment of SARS infection is disclosed. The compounds are effective to inhibit cytokine production and thereby reduce symptoms, particularly in the immune hyperactive phase of the disease.
PCT/US2004/020447 2003-06-27 2004-06-25 Method for treatment of severe acute respiratory syndrome WO2005020887A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48333503P 2003-06-27 2003-06-27
US60/483,335 2003-06-27

Publications (2)

Publication Number Publication Date
WO2005020887A2 WO2005020887A2 (en) 2005-03-10
WO2005020887A3 true WO2005020887A3 (en) 2005-04-28

Family

ID=33552053

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2004/020347 WO2005000291A1 (en) 2003-06-27 2004-06-25 Method for treatment of idiopathic pulmonary fibrosis using triptolide derivatives
PCT/US2004/020447 WO2005020887A2 (en) 2003-06-27 2004-06-25 Method for treatment of severe acute respiratory syndrome

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2004/020347 WO2005000291A1 (en) 2003-06-27 2004-06-25 Method for treatment of idiopathic pulmonary fibrosis using triptolide derivatives

Country Status (1)

Country Link
WO (2) WO2005000291A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7847109B2 (en) 2002-05-31 2010-12-07 Pharmagenesis, Inc. Triptolide derivatives for modulation of apoptosis and immunosuppression
US6943259B2 (en) 2003-02-25 2005-09-13 Pharmagenesis, Inc. Halogenated triptolide derivatives as immunomodulators and anticancer agents
WO2005062913A2 (en) 2003-12-24 2005-07-14 Pharmagenesis, Inc. Triplide 5,6-derivatives as immunomodulators and anticancer agents
CN1917893A (en) 2004-02-09 2007-02-21 美国泛华医药公司 Methods for isolation of triptolide compounds from tripterygium wilfordii
ATE554758T1 (en) 2004-03-02 2012-05-15 Pharmagenesis Inc TRIPTOLIDE-LACTONE RING DERIVATIVES AS IMMUNE MODULATORS AND ANTI-CANCER AGENT
WO2006044496A2 (en) 2004-10-13 2006-04-27 Pharmagenesis, Inc. Identification and screening of triptolide target molecules
US8268882B2 (en) 2009-02-05 2012-09-18 Pharmagenesis, Inc. Triptolide C-ring derivatives as anticancer agents and immune modulators
US9150600B2 (en) 2009-05-07 2015-10-06 Regents Of The University Of Minnesota Triptolide prodrugs
JP6000122B2 (en) 2009-05-07 2016-09-28 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Triptolide products
CN107663225A (en) * 2016-07-29 2018-02-06 欣凯医药化工中间体（上海）有限公司 A kind of fluoro triptolide lactone ring derivatives
WO2018222351A1 (en) * 2017-05-27 2018-12-06 Pharmagenesis, Inc. Triptolide lactone derivatives as immunomodulators and anticancer agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150539A (en) * 1998-09-02 2000-11-21 Pharmagenesis, Inc. Triptolide prodrugs having high aqueous solubility

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150539A (en) * 1998-09-02 2000-11-21 Pharmagenesis, Inc. Triptolide prodrugs having high aqueous solubility

Also Published As

Publication number Publication date
WO2005020887A2 (en) 2005-03-10
WO2005000291A1 (en) 2005-01-06
WO2005000291A8 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
NL300933I2 (en) Letermovir
WO2005063734A3 (en) Substituted thiophenes
WO2006072347A3 (en) Alkinyl-substituted thiophenes
WO2005023083A3 (en) Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2006015035A8 (en) Useful compounds for hpv infection
WO2007041130A3 (en) Deazapurines useful as inhibitors of janus kinases
TW200621765A (en) Substituted phenylaminothiazoles and their use
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
WO2004022537A3 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
WO2006058648A3 (en) Biaryloxymethylarene carboxylic acids
WO2004071382A3 (en) Substituted heterocycles
WO2006072348A3 (en) Alkinyl-substituted thiophenes
AU2003297048A1 (en) Cyclohexyl compounds as ccr5 antagonists
WO2005056547A3 (en) Quinoxalines useful as inhibitors of protein kinases
WO2007075833A3 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
WO2005020887A3 (en) Method for treatment of severe acute respiratory syndrome
WO2006023843A3 (en) Novel heterocycles
WO2006089664A3 (en) Heterocyclylamide-substituted imidazoles
WO2004087700A8 (en) Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain
MXPA05013200A (en) Staurosporine derivatives for hypereosinophilic syndrome.
WO2006136428A3 (en) Method and composition to treat skin ulcers
WO2005082884A3 (en) 2-pyridin-2yl-pyrimidine derivatives useful in the treatment of gastro-esophagea l reflux disease
EA200500326A1 (en) APPLICATION OF FERMENTED EXTRACT OF WHEAT SPIRITS AS AN ANTI-INFLAMMATORY AGENT
WO2002058707A3 (en) Method of treatment of type i diabetes with vitamin d compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase